Sunshine Heart Adopts Stockholder Rights Plan

Sunshine Heart Adopts Stockholder Rights Plan

EDEN PRAIRIE, Minn., June 14, 2013 (GLOBE NEWSWIRE) -- Sunshine Heart, Inc.
(Nasdaq:SSH) today announced that its Board of Directors adopted a stockholder
rights plan (the "Rights Plan" or "Plan") and declared a dividend distribution
of one right ("Right") for each outstanding share of Sunshine Heart common

The Rights Plan is intended to protect the Company and its stockholders from
efforts to obtain control of Sunshine Heart that its Board of Directors
determines are not in the best interests of the Company and its stockholders,
and to enable all stockholders to realize the long-term value of their
investment in Sunshine Heart. The Rights Plan is not intended to interfere
with any merger, tender or exchange offer or other business combination
approved by the Board of Directors.

Pursuant to the Plan, Sunshine Heart is issuing one Right for each current
share of common stock outstanding at the close of business on June 24, 2013.
Initially, these rights will not be exercisable and will trade with the shares
of the Company's common stock. If the Rights become exercisable, each Right
will entitle stockholders to buy one one-thousandth of a share of a new series
of participating preferred stock at an exercise price of $35 per one
one-thousandth of a share ("exercise price").

The Rights will be exercisable only if a person or group acquires 15% or more
of Sunshine Heart's common stock in a transaction not approved by the
Company's Board of Directors. If a person or group acquires 15% or more of
Sunshine Heart's outstanding common stock, each Right will entitle its holder
(other than such person or members of such group) to purchase, at the exercise
price (subject to adjustment as provided in the Plan), a number of shares of
the Company's common stock having an aggregate market value equal to twice the
then-current exercise price.

In addition, if after a person or group acquires 15% or more of Sunshine
Heart's outstanding common stock, Sunshine Heart merges into another company,
an acquiring entity merges into Sunshine Heart or Sunshine Heart sells or
transfers more than 50% of its consolidated assets, cash flow or earning
power, then each Right will entitle the holder thereof to purchase, at the
exercise price (subject to adjustment as provided in the Plan), a number of
shares of common stock of the person engaging in the transaction having an
aggregate market value equal to twice the then-current exercise price. The
acquiring person will not be entitled to exercise the Rights.

The Rights will expire on June 14, 2016, unless the Rights are earlier
redeemed or exchanged by the Company.

Additional details about the Rights Plan will be contained in a Form 8-K to be
filed by Sunshine Heart with the U.S. Securities and Exchange Commission.

Honigman Miller Schwartz and Cohn LLP is serving as legal counsel to the

About Sunshine^® Heart

Sunshine Heart, Inc. (Nasdaq:SSH) is an early-stage medical device company
focused on developing, manufacturing and commercializing the C-Pulse System
for treatment of Class III and ambulatory Class IV heart failure. Sunshine
Heart has completed an approved U.S. Food and Drug Administration (FDA)
feasibility clinical trial of the C-Pulse System and presented the results in
November2011. In March 2012, the FDA notified the Company that it could move
forward with an investigational device exemption (IDE) application. Sunshine
Heart received unconditional approval from the FDA in November2012 to
initiate its pivotal trial. In July2012 Sunshine Heart received CE Mark
approval for its C-Pulse System in Europe. Sunshine Heart is a Delaware
corporation headquartered in Minneapolis with a wholly owned subsidiary in
Australia. The Company has been listed on the NASDAQ Capital Market since

About the C-Pulse^® Heart Assist System

The C-Pulse Heart Assist System, or C-Pulse System, an investigational device
in the United States, Canada and countries that do not recognize the CE mark
approval, utilizes the scientific principles of intra-aortic balloon
counter-pulsation applied in an extra-aortic approach to assist the left
ventricle by reducing the workload required to pump blood throughout the body,
while increasing blood flow to the coronary arteries.Combined, these
potential benefits may help sustain the patient's current condition or, in
some cases, reverse the heart failure process, thereby potentially preventing
the need for later-stage heart failure devices, such as left ventricular
assist devices (LVADs), artificial hearts or transplants. It may also provide
relief from the symptoms of Class III and ambulatory Class IV heart failure
and improve quality of life and cardiac function. Based on the results from
our feasibility trial, we also believe that some patients treated with our
C-Pulse System will be able to stop using the device due to sustained
improvement in their conditions as a result of the therapy.

Caution: Investigational device, limited by Federal (or United States) Law to
Investigational use.

Forward-Looking Statements

Certain statements in this release are forward-looking statements that are
based on management's beliefs, assumptions and expectations and information
currently available to management. All statements that address future
operating performance, events or developments that we expect or anticipate
will occur in the future are forward-looking statements, including, without
limitation, our expectations with respect to future clinical trial activities
and results including patient enrollment in trials. These forward-looking
statements are subject to numerous risks and uncertainties, including, without
limitation, the possibility that our clinical trials do not meet their
enrollment goals, meet their end-points or otherwise fail, that regulatory
authorities do not accept our application or approve the marketing of the
C-Pulse System, the possibility that we may be unable to raise the funds
necessary for the development and commercialization of our products, that we
may not be able to commercialize our products successfully in the EU and the
other risk factors described under the caption "Risk Factors" and elsewhere in
our filings with the Securities and Exchange Commission. You should not place
undue reliance on forward-looking statements because they speak only as of the
date when made and may turn out to be inaccurate. We do not assume any
obligation to publicly update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise. We may not
actually achieve the plans, projections or expectations disclosed in
forward-looking statements, and actual results, developments or events could
differ materially from those disclosed in the forward-looking statements.

         Laura Forman
         Blueprint Life Science Group
         T: +1-415-375-3340
         Jeff Mathiesen
         Chief Financial Officer
         Sunshine Heart, Inc.
         T: +1-952-345-4200

Sunshine Heart logo
Press spacebar to pause and continue. Press esc to stop.